Research location
Livorno
LI, Italy
Advertisement
Research activity in Livorno
LI, ItalyCureCurrent currently publishes aggregate city-level research activity for this location: 7 trials and 7 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Livorno
7 linked trials · page 1 of 1BRING-UP 3 Heart FailureNCT06279988 · 2023-09-15 · 1 site observation
UNKNOWN
Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus FulvestrantNCT03439046 · 2018-02-02 · 1 site observation
TERMINATED
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCNCT02941926 · 2016-11-30 · 1 site observation
COMPLETED
A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to LeptomeningesNCT02336451 · 2015-04-01 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD RegimenNCT01985334 · 2014-02-14 · 1 site observation
COMPLETED
LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and CrizotinibNCT01685060 · 2012-11-26 · 1 site observation
COMPLETED
GISSI-HF- Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic CHFNCT00336336 · 2002-08-01 · 1 site observation
COMPLETED
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.